Number of Metabolic Syndrome Risk Factors Influences Risk for Prostate Cancer

VBCC - September 2013, Volume 4, No 7 - Prostate Cancer
Rosemary Frei, MSc

Niagara Falls, Ontario—Previous studies have shown an association between metabolic syndrome and prostate cancer. A study presented at the 2013 Canadian Urological Association annual meeting during a poster presentation investigated the level of prostate cancer risk in relation to the number of risk factors of metabolic syndrome and prostate cancer grade.

The results suggest that the risk for prostate cancer increases in stepwise fashion with each additional metabolic syndrome risk factor. A stepwise increase in the risk of clinically significant prostate cancer or high-grade prostate cancer was associated with 1, 2, and then ≥3 risk factors. Only ≥3 risk factors reached statistical significance, however.

Lead investigator Neil E. Fleshner, MD, MPH, Head, Division of Urology, University Health Network, Toronto, Canada, and colleagues, focused on men whose biopsy samples are included in the Genito-Urinary BioBank at the Princess Margaret Hospital in Toronto.

The researchers did not include men on active surveillance. A total of 2144 patients were included in the analysis, and 1301 (60.7%) of them were diagnosed at biopsy with prostate cancer. Among the men with prostate cancer, 593 had a Gleason score of ≥7.

The odds ratio for developing clinically significant or high-grade prostate cancer was calculated for 5 components of metabolic syndrome—elevated fasting glucose concentration or diabetes, obesity, elevated levels of triglycerides, low concentration of high-density lipoprotein cholesterol, and hypertension. None of the odds ratios were statistically significant.

The risk for developing prostate cancer was 38% higher with ≥3 risk factors for metabolic syndrome than with none; the risk was 52% higher for clinically significant prostate cancer, and 43% higher for high-grade prostate cancer. Furthermore, there was a stepwise, but not significant, increase in prostate cancer risk between having no metabolic syndrome risk factors and 1 risk factor, and between zero or 1 risk factor and 2 risk factors.

Related Items
Poor Pregnancy Outcomes Seen in Women with Childhood-Onset SLE
Rosemary Frei, MSc
VBCR - April 2016, Vol 5, No 2 published on May 23, 2016 in Canadian Rheumatology Association Annual Meeting
Addressing Undertreatment of Patients with Gout Using EMR Data
Rosemary Frei, MSc
VBCR - April 2016, Vol 5, No 2 published on May 11, 2016 in Canadian Rheumatology Association Annual Meeting
Six-Month OBSErve Study Results Indicate Positive Effects of Belimumab in SLE
Rosemary Frei, MSc
VBCR - April 2016, Vol 5, No 2 published on May 8, 2016 in Canadian Rheumatology Association Annual Meeting
Improvements Needed in Access to Timely Quality Care
Rosemary Frei, MSc
VBCR - April 2016, Vol 5, No 2 published on May 7, 2016 in Canadian Rheumatology Association Annual Meeting
Orthotics Reduce Foot Pain in Juvenile Idiopathic Arthritis
Rosemary Frei, MSc
VBCR - April 2016, Vol 5, No 2 published on May 4, 2016 in Juvenile Idiopathic Arthritis
Increased Physical Activity May Help Extend Survival After Prostate Cancer Diagnosis
Charles Bankhead
VBCC - March 2016, Vol 7, No 2 published on March 21, 2016 in Prostate Cancer
Regular Aspirin Use Reduces the Risk for Prostate Cancer Death
Phoebe Starr
VBCC - March 2016, Vol 7, No 2 published on March 21, 2016 in Prostate Cancer
Biosimilar Infliximab Recommended for Approval
Rosemary Frei, MSc
VBCR - February 2016, Vol 5, No 1 published on March 15, 2016 in FDA Approvals, News & Updates
Early Response to Abatacept Detectable by Sophisticated Ultrasound
Rosemary Frei, MSc
VBCR - February 2016, Vol 5, No 1 published on March 15, 2016 in Rheumatoid Arthritis
Updated Recommendations for Pharmacologic Treatment of Patients with Psoriatic Arthritis
Rosemary Frei, MSc
VBCR - February 2016, Vol 5, No 1 published on March 15, 2016 in Psoriatic Arthritis
Last modified: May 28, 2014
  • Rheumatology Practice Management
  • American Health & Drug Benefits
  • Value-Based Cancer Care
  • Value-Based Care in Myeloma
  • Value-Based Care in Neurology